Middlesex Water Reports 2025 Results, Secures Major Rate Hikes & $506M Capital Plan

summarizeSummary

Middlesex Water filed its 2025 annual report, detailing a slight EPS decline but highlighting significant approved rate increases, a substantial capital investment program, and successful financing efforts to support future growth and regulatory compliance.

check_boxKey Events

• 2025 Financial Results

  Reported diluted EPS of $2.36 for 2025, a decrease from $2.47 in 2024, alongside a modest 1.46% increase in operating revenues to $194.7 million.

• Significant Rate Increases Approved

  The NJBPU approved $14.5 million in base rate increases for New Jersey operations (effective Feb 2026) and the DEPSC approved $5.5 million for Delaware operations (effective July 2025), significantly boosting future revenue.

• Major Capital Investment Program

  Plans to invest approximately $506 million in capital projects through 2028, including $255 million for PFAS treatment, with $126 million allocated for 2026. New regulatory charges (RESIC and DSIC) will facilitate cost recovery for these investments.

• Successful Financing Activities

  Raised $29.5 million in net proceeds from an At-The-Market (ATM) equity offering in 2025 and secured authorization for up to $260 million in new long-term debt for 2026-2028, along with an increased line of credit to $180 million.

auto_awesomeAnalysis

This annual 10-K filing provides a comprehensive overview of Middlesex Water's 2025 financial performance and outlines significant strategic developments for future growth and regulatory compliance. While diluted EPS saw a slight decline, the company secured substantial rate increases in both New Jersey ($14.5M) and Delaware ($5.5M), which are critical for a regulated utility's revenue stability. The approval of new cost recovery mechanisms (RESIC and DSIC) and a massive $506 million capital investment program through 2028, including significant spending on PFAS treatment, demonstrates a clear path for infrastructure modernization and regulatory adherence. The successful execution of an At-The-Market equity offering and new debt authorizations ensures funding for these initiatives. Investors should focus on the forward-looking impact of these regulatory approvals and capital investments, which are expected to drive future earnings and operational efficiency.